Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578593 | 0.84 | L3MBTL1 (1.00) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL30416315 | 0.81 | L3MBTL1 (0.97) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL16371035 | 0.81 | L3MBTL1 (0.97) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL10772770 | 0.79 | L3MBTL1 (0.82) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL13033200 | 0.79 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL24378058 | 0.78 | PKM (0.84) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL8356145 | 0.78 | PKM (0.84) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL6484472 | 0.77 | MAPK14 (0.58) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A | |
| SCHEMBL13033217 | 0.77 | PRMT5 (0.80) | — | |
| SCHEMBL4578170 | 0.76 | USP2 (0.83) | L3MBTL1SMN1; SMN2MAPK1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498599-B1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS | 2010-11-04 | — | — | US | disclosed |
| WO-2010051374-A1 | ANALGESIC THAT BINDS FILAMIN A | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279997-A1 | ANALGESIC THAT BINDS FILAMIN A | FLNA, FLNB, OPRL1 | L3MBTL1 1166/4885SMN1; SMN2 843/4885MAPK1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.